Menopause

Understanding the Menopausal Transition in Clinical Practice

Menopause is a natural biological transition marking the permanent cessation of menstrual cycles due to loss of ovarian follicular function. For the Family Nurse Practitioner (FNP), managing menopausal symptoms and providing long-term preventive care is a high-yield exam and clinical priority. Approximately 6,000 U.S. women reach menopause daily, and many seek primary care guidance for symptom relief, hormone therapy decisions, and chronic disease risk reduction.[1]

Essential Terminology for Menopausal Stages

  • Menopause: Retrospectively diagnosed after 12 consecutive months of amenorrhea without other causes.[2]
  • Perimenopause: Transition phase of varying length (average 4–8 years) marked by irregular cycles, vasomotor symptoms, and hormonal fluctuations.[3]
  • Postmenopause: Period after final menses; associated with increased cardiovascular and bone health risks.
  • Early menopause: Occurs between ages 40–45.
  • Premature ovarian insufficiency (POI): Menopause before age 40; requires workup for autoimmune, genetic, or iatrogenic causes.[4]
  • Hormone therapy (HT): Systemic estrogen (with progestogen if uterus intact) for vasomotor symptom management and osteoporosis prevention.

Diagnostic Staging and Hormonal Changes in Menopause

Staging (STRAW+10 Criteria)

  1. Reproductive stage: Regular menstrual cycles.
  2. Early perimenopause: Persistent ≥7-day change in cycle length.
  3. Late perimenopause: ≥60 days of amenorrhea.
  4. Final menstrual period (FMP).
  5. Early postmenopause (first 1–5 years): Rapid bone loss and peak vasomotor symptoms.
  6. Late postmenopause (>5 years): Increased cardiovascular and fracture risk.[5]

Hormonal Changes

Declining inhibin B and rising FSH are the earliest biomarkers. Estradiol levels become low and variable. A single FSH > 25 IU/L (on two occasions) supports diagnosis in amenorrhea without other causes; however, laboratory confirmation is not required for typical clinical presentation.[6]

Recognizing the Multisystem Effects of Menopause

  • Vasomotor symptoms (VMS): Hot flashes, night sweats – affect up to 80% of women; most bothersome in late perimenopause and early postmenopause.[1]
  • Genitourinary syndrome of menopause (GSM): Vaginal dryness, dyspareunia, urinary urgency/frequency, recurrent UTIs.
  • Sleep disturbances: Often secondary to night sweats, but also primary insomnia.
  • Mood changes: Increased risk of depressive symptoms, especially in women with history of mood disorders.[7]
  • Cognitive complaints: Forgetfulness, difficulty concentrating (often transient).
  • Joint and muscle aches.
  • Metabolic changes: Increased central adiposity, decreased lean body mass.

History, Physical, and Diagnostic Testing in Menopause

  • History: Menstrual pattern, symptom severity (e.g., hot flash frequency/impact), sexual function, psychosocial context.
  • Physical exam: BMI, BP, pelvic exam (atrophy), breast exam.
  • Diagnostic tests (when indicated):
    • FSH (not routinely needed if classic age >45 and amenorrhea >1 year).
    • TSH to rule out thyroid dysfunction.
    • Lipid panel, fasting glucose, vitamin D, bone density (DXA) based on risk factors.[8]
    • Pregnancy test in perimenopausal women with amenorrhea.
  • Risk stratification: Use tools like FRAX for fracture risk; ASCVD risk calculator for cardiovascular disease.[9]

Therapeutic Approaches for Menopause Management

Hormone Therapy (HT)

  • Indications: Moderate-to-severe VMS; prevention of bone loss in women at high fracture risk when nonestrogen therapies are inappropriate.[10]
  • Regimens:
    • Estrogen-only (ET): For women after hysterectomy.
    • Estrogen plus progestogen (EPT): For women with intact uterus (to prevent endometrial hyperplasia).
  • Routes: Oral, transdermal patch/gel, vaginal (for GSM only). Transdermal may have lower thromboembolic risk.[10]
  • Contraindications: Breast cancer history, active VTE, liver disease, unexplained uterine bleeding, pregnancy, high-risk endometrial cancer.
  • Timing: Initiate within 10 years of menopause and before age 60 for optimal risk-benefit ratio.[11]

Nonhormonal Pharmacotherapy for VMS

  • SSRIs/SNRIs: Paroxetine 7.5 mg (approved by FDA for VMS), venlafaxine, escitalopram – modest symptom reduction.
  • Gabapentin/pregabalin: Effective for VMS, especially for those with sleep disruption.
  • Clonidine: Older option, limited by side effects (hypotension, dry mouth).[12]
  • Fezolinetant: Neurokinin-3 receptor antagonist; recently approved for nonhormonal VMS treatment.[13]

Genitourinary Syndrome Management

  • First-line: Water-based lubricants and vaginal moisturizers.
  • Low-dose vaginal estrogen: Cream, tablet, or ring – minimal systemic absorption; safe for most women, including some breast cancer survivors (after oncology discussion).[14]
  • Ospemifene: Oral SERM for dyspareunia.
  • Vaginal DHEA (prasterone): Treats moderate-to-severe dyspareunia.

Lifestyle and Complementary Approaches

  • Weight-bearing exercise and resistance training for bone and muscle health.
  • Calcium (1,200 mg/d) and vitamin D (600–800 IU/d) through diet and supplements if intake inadequate.[8]
  • Cognitive behavioral therapy (CBT) and hypnosis for hot flashes and sleep.
  • Dietary phytoestrogens: Limited evidence; may consider but not substitute for pharmacotherapy.
  • Acupuncture, yoga: Supportive evidence variable; may improve quality of life.

Understanding Risks and Contraindications in Menopause Therapy

  • Venous thromboembolism (VTE): Risk increased with oral estrogen (especially in women with obesity, immobility, or thrombophilia).[10]
  • Endometrial cancer: Unopposed estrogen in women with a uterus is contraindicated; must use adequate progestogen.
  • Breast cancer: Risk slightly elevated with combined HT beyond 5 years; absolute risk varies by age and baseline risk profile.[11]
  • Cardiovascular disease: HT should not be initiated for primary prevention; may increase coronary events if initiated after age 60 or >10 years postmenopause.[11]
  • Osteoporosis: Postmenopausal women should be screened with DXA at age 65 (or earlier with risk factors).[8]
  • Depression: Screen regularly using PHQ-9; consider therapy or antidepressants if indicated.

Essential Exam Takeaways for Menopause Management

  • Definition: 12 months amenorrhea – memorize this exam classic.
  • Counseling: Menopause is a normal event; HT decisions are individualized based on symptoms, age (<60), time since menopause (<10 years), and contraindications.
  • First-line for VMS: Systemic HT for candidates; for those with contraindications or preference, consider fezolinetant or low-dose paroxetine.
  • No routine FSH needed in a 52-year-old with typical symptoms and amenorrhea.
  • Genitourinary syndrome: Do not prescribe systemic HT just for vaginal symptoms – use low-dose vaginal estrogen.
  • Cardiovascular risk: Menopause increases CVD risk; assess and manage BP, lipids, glucose, and lifestyle aggressively.
  • Bone health: DXA at 65; earlier if POI, BMI <18.5, smoking, chronic steroid use, or history of fragility fracture.[8]
  • Memory aid – “The 4 Ms”: Menstrual changes, Mood swings, Metabolic shifts, and Muscle/joint aches.

References

  1. North American Menopause Society. Menopause Practice: A Clinician’s Guide, 6th ed. NAMS; 2019. https://www.scribd.com/document/884113802/Clinician-s-Guide-6th-Edition92d500873a01675a99cbff00005b8a07
  2. ACOG Practice Bulletin No. 141: Management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202-216. Reaffirmed 2020. https://doi.org/10.1097/01.AOG.0000441353.20693.78
  3. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10. Menopause. 2012;19(4):387-395. https://doi.org/10.1097/gme.0b013e31824d8f40
  4. Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926-937. https://doi.org/10.1093/humrep/dew027
  5. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril. 2001;76(5):874-878. https://doi.org/10.1016/S0015-0282(01)02909-0
  6. American Association of Clinical Endocrinologists. AACE/ACE Guidelines for the diagnosis and treatment of menopause. Endocr Pract. 2017;23(Suppl 2):1-87. https://pubmed.ncbi.nlm.nih.gov/28703650/
  7. Freeman EW. Associations of depression with the transition to menopause. Menopause. 2010;17(4):823-827. https://doi.org/10.1097/gme.0b013e3181db9f8b
  8. US Preventive Services Task Force. Screening for osteoporosis to prevent fractures: USPSFT recommendation statement. JAMA. 2018;319(24):2521-2531. https://doi.org/10.1001/jama.2018.7498
  9. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625
  10. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753. https://doi.org/10.1097/GME.0000000000000921
  11. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative. JAMA. 2017;318(10):927-938. https://doi.org/10.1001/jama.2017.11217
  12. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295(17):2057-2071. https://doi.org/10.1001/jama.295.17.2057
  13. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 study. Lancet. 2023;401(10378):1091-1102. https://pubmed.ncbi.nlm.nih.gov/36924778/
  14. ACOG Committee Opinion No. 659: The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127(3):e93-e96. https://doi.org/10.1097/AOG.0000000000001351

Ready to test your knowledge?

Master the core responsibilities, scope of practice, and limitations for the Family Nurse Practitioner exam.

Start Practice Questions
Previous Topic Next Topic